The Next Generation
Thomas Rohrer at Lonza highlights the advantages of antibody drug conjugates, but cautions that these highly potent biopharmaceuticals present a series of unique manufacturing challenges due to their potency
and the raw material supply chain.
Thomas Rohrer, Lonza (June 2013)
Keywords: Antibody drug conjugate (ADC)
Monoclonal antibody (mAb)
Maximum acceptable carryover (MAC) calculation